---
title: "EMD Serono erhält FDA-Kommissionsgutschein für Pergoveris"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275129071.md"
datetime: "2026-02-06T13:01:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275129071.md)
  - [en](https://longbridge.com/en/news/275129071.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275129071.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275129071.md) | [English](https://longbridge.com/en/news/275129071.md)


# EMD Serono erhält FDA-Kommissionsgutschein für Pergoveris

EMD Serono, die Healthcare-Sparte von Merck KGaA, Darmstadt, Deutschland, hat in den USA von der FDA einen Commissioner’s National Priority Voucher (CNPV) für das Fertilitätsprodukt Pergoveris® (follitropin alfa/lutropin alfa) erhalten. Dieses Produkt ist in vielen Ländern außerhalb der USA verfügbar und stellt eine potenzielle therapeutische Option für die follikuläre Entwicklung bei Frauen dar, die sich einer ovariellen Stimulation unterziehen und für eine gleichzeitige Therapie mit FSH und LH in Frage kommen. Der Voucher ist Teil einer Initiative zur beschleunigten Überprüfung von Arzneimitteln, die mit nationalen Gesundheitsprioritäten in den USA übereinstimmen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260206377885) on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Merck (MRK.US)](https://longbridge.com/zh-HK/quote/MRK.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Merck (MKKGY.US)](https://longbridge.com/zh-HK/quote/MKKGY.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer](https://longbridge.com/zh-HK/news/281517399.md)
- [Infinimmune, Merck enter into antibody discovery pact](https://longbridge.com/zh-HK/news/281193725.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio]]>](https://longbridge.com/zh-HK/news/280521246.md)
- [WESPAC Advisors LLC Makes New $2.93 Million Investment in Merck & Co., Inc. $MRK](https://longbridge.com/zh-HK/news/281011423.md)
- [ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH](https://longbridge.com/zh-HK/news/281541014.md)